PMV Pharmaceuticals (PMVP) Gets a Buy from Oppenheimer

Tip Ranks
2025.11.13 14:36
portai
I'm PortAI, I can summarize articles.

Oppenheimer's Jeff Jones maintains a Buy rating on PMV Pharmaceuticals with a $6.00 price target. The analyst consensus is a Strong Buy with an average target of $5.00. Jones, who covers the Healthcare sector, has a 3.4% average return and a 42.19% success rate on stock recommendations.

In a report released today, Jeff Jones from Oppenheimer maintained a Buy rating on PMV Pharmaceuticals, with a price target of $6.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Jones covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Corbus Pharmaceuticals, and Pelthos Therapeutics. According to TipRanks, Jones has an average return of 3.4% and a 42.19% success rate on recommended stocks.

Currently, the analyst consensus on PMV Pharmaceuticals is a Strong Buy with an average price target of $5.00.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer